In this study, we investigated the in vitro anti-inflammatory and antibacterial effects of the MEK1/2 inhibitor compound ATR-002 utilizing human CF macrophages and clinical isolates of S. aureus. Here, MAP2K1 is linked to cystic fibrosis.